Background: The effects of sotalol on the 24-hour profile of the QT interval relative to that of the heart rate (HR) may be helpful in determining the time course of the drug's action in controlling cardiac arrhythmias. This has not been previously determined. Thus, the objec tive of the current study was to evaluate the influence of the drug on the circadian rhyth micity of HR and QT intervals from Holter recordings in ambulatory patients. Reverse-use dependency (RUD) of sotalol was also studied noninvasively from Holter recordings.
Methods and Results: Holter recordings of 18 patients with ventricular arrhythmias were analyzed before and after 3-7 days of treatment with sotalol. We developed and used a sig nal processing system. A new noninvasive index to evaluate RUD was defined and applied to sotalol as a test agent. Sotalol significantly reduced HR from 76.9 ± 3.2 to 60.0 ± 1.1 (P < .001). The mean QT interval increased from 393 ± 11 ms to 489 ± 9 ms, whereas the mean normalized QT (QTc) interval increased from 415 ± 5 ms to 487 ± 5 ms (P < .001) during the drug treatment. Circadian rhythmicity of RR interval was abolished, but the circadian rhythms of the QT and QTc intervals were maintained during continuous treatment with sotalol. This finding is in contrast to amiodarone, which abolished the circadian rhythmicity of QTc interval while maintaining that of RR interval. RUD index was increased from 0.13 ± 0.08 to 0.24 ± 0.10 (P < .001) after sotalol, consistent with increased RUD with sotalol.
Conclusions: The effects of sotalol on the circadian rhythmicity of HR and QTc interval are dissociated. They are in direct contrast to those reported for amiodarone, a difference that may be of clinical significance. The RUD index introduced here provides a noninvasive parameter for comparing short-term as well as long-term effects of class III antiarrhythmic drugs on RUD.
Podrid PJ, Fuchs T., Candinas R.Role of the sympathetic nervous system in the genesis of ventricular arrhythmia . Am J Cardiol82:103, 1993
2.
Willich SN, Levy D., Rocco MB, et al. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol60:801, 1987
3.
Muller JE, Ludmer PL, Willich SN, et al. Circadian variation in the frequency of sudden cardiac death . Am J Cardiol75:131, 1987
4.
Willich SN, Maclure M., Mittleman M., et al. Sudden cardiac death: support for a role of triggering in causation . Am J Cardiol87:1442, 1993
5.
Kleiger RE, Miller JP, Bigger Jtj, et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol59: 256, 1987
6.
Yusuf S., Venkatesh G., Teo KSCritical review of the approaches to the prevention of sudden death. Am J Cardiol72:51F, 1993
7.
Singh BNAdvantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction. Am J Cardiol66:9C, 1990
8.
Hallstrom AP , Cobb LA, Yu BH, et al. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol68:1025,1991
9.
Hennekins CH , Godfried SL, Albert CM, et al. Adjunctive drug therapies during and post acute myocardial infarction. N Engl J Med335:1660, 1996
10.
Yusuf S., Peto R., Lewis J., et al. Beta-blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis27:335, 1985
11.
Chadda K., Goldstein S., Byington R., et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation73:503, 1986
12.
Packer M., Colucci WS, Sackner-Bernstein JD, et al. Double-blind-placebo-controlled study of the effects of carvedilol in patients with moderate and severe heart failure: The PRECISE trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation94: 2793, 1996
13.
Herre JM, Sauve MJ, Malone P., et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol12:442, 1989
14.
Singh BN (ed). Control of Cardiac Arrhythmias by Lengthening Repolarization. Futura Publishing, Mt. Kisco, NY, 1988
15.
Nademanee K. , Stevenson W., Weiss JN, et al. The role of amiodarone in the survivors of sudden arrhythmic deaths. In Singh BN (ed). Control of cardiac arrhythmias by lengthening repolarization . Futura Publishing, Mt. Kisco, NY, pp. 489-508, 1988
16.
Nademanee K. , Singh BN, Hendrickson J., et al. Amiodarone in refractory life-threatening ventricular arrhythmias. Ann Intern Med98:577, 1983
17.
Singh BNAntiarrhythmic drugs: A re-orientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol81:3D, 1998
18.
Antimisiaris M., Sarma Jsm, Schoenbaum MP, et al. Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: Significance for the control of sudden cardiac death. Am Heart J128:884, 1994
19.
Singh BNHistorical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: Particular reference to sotalol. Am J Cardiol65:3A, 1990
20.
Hondeghem LM , Snyders DJClass III antiarrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use dependence. Am J Cardiol81:686,1990
21.
Funck-Brentano C., Kibleur Y., Coz FL, et al. Rate dependence of sotolol-induced prolongation of ventricular repolarization during exercise in humans. Am J Cardiol83:536,1991
22.
Sicouri S., Moro S., Litovsky S., et al. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol8:1269, 1997
23.
Sarma Jsm, Singh N., Shoenbaum MP, et al. Circadian and power spectral changes of RR and QT intervals during treatment of patients with angina pectoris with nadolol providing evidence for differential autonomic modulation of heart rate and ventricular repolarization . Am J Cardiol74:131, 1994
24.
Balasubramanian BVClinical and research applications of ambulatory Holter ST-segment and heart rate monitoring. Am J Cardiol58:11B, 1986
25.
Woosley RL, Barbey JT, Wang T., et al. Concentration/ response relations for the multiple antiarrhythmic actions of sotalol. Am J Cardiol65:22A, 1990
26.
Singh BN (ed). Controlling cardiac arrhythmias with sotalol, a broad-spectrum antiarrhythmic with beta-blocking effects and class III activity. Am J Cardiol65:35A, 1990
27.
Charlier R.Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors . Br J Pharmacol39:668,1970
28.
Hohnloser SH , Klingenheben T., Singh BNAmiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern Med121:529, 1994
29.
Kodama I., Kamiya K., Toyoma J.Cellular electrophysiology of amiodarone. Cardiovasc Res35:13, 1997
30.
Cui G., Sen L., Sager PT, et al. Effects of amiodarone, sematilide, and sotalol on QT dispersion . Am J Cardiol74:896,1994
31.
Hohnloser SHProarrhythmia with class III antiarrhythmic drugs: Types, risks and management. Am J Cardiol80:82G, 1997
32.
Schmitt C., Brachmann J., Karch M., et al. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle. Am J Cardiol68:1183, 1991
33.
Sen L., Cui G., Sakaguchi Y., et al. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs. J Pharmacol Exp Ther285:687, 1998
